Neoadjuvant chemotherapy is alternative treatment option to upfront cytoreductive surgery to
treat advanced ovarian cancer. Paclitaxel plus carboplatin is most frequently selected
chemotherapeutic regimen for neoadjuvant chemotherapy. Docetaxel had similar therapeutic
efficacy compared to paclitaxel in adjuvant chemotherapy trials in ovarian cancer. However,
docetaxel had more favorable toxicity profile. Therefore, the investigators aimed to evaluate
the efficacy of docetaxel plus carboplatin as neoadjuvant chemotherapy in patients with
advanced ovarian cancer.